X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Zynlonta (loncastuximab tesirine-lpyl), an antibody-drug conjugate (ADC) targeting CD19, is approved by FDA and EU for the treatment of adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL).
Lead Product(s): Loncastuximab Tesirine
Therapeutic Area: Oncology Product Name: Zynlonta
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: ADC Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 24, 2023
Details:
ZYNLONTA® (loncastuximab tesirine-lpyl) is a CD19-directed antibody drug conjugate (ADC). Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload.
Lead Product(s): Loncastuximab Tesirine,Rituximab
Therapeutic Area: Oncology Product Name: Zynlonta
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: ADC Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 11, 2022
Details:
ADC Therapeutics licensed exclusive development and commercialization rights to Lonca, ADCT-602, ADCT-601 and ADCT-901 for greater China and Singapore to Overland ADCT BioPharma. Overland Pharmaceuticals will have a 51% stake and ADC Therapeutics, 49%.
Lead Product(s): Loncastuximab Tesirine,Rituximab
Therapeutic Area: Oncology Product Name: Lonca
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Overland ADCT BioPharma
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Agreement December 14, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
